- Central planning meets the Drug War: Drug Enforcement Administration (DEA) presumes to know and decree “just how many prescription opioids of all classifications and in all situations will be needed in the coming year for a nation of 325 million people.” Paging Dr. Hayek [Jeffrey Singer]
- Mysteries of the “negotiating class”: National Association of Attorneys General questions novel procedural device used by federal judge Dan Polster in Cleveland [Daniel Fisher, Legal Newsline, more; Amanda Bronstad, Law.com (Sixth Circuit review)]
- “All of these are drug-seeking behaviors. But I maintain that none of these patients were addicted.” Scott Alexander talks back to a U.S. Senator, the WSJ, and others [Slate Star Codex] “How Stigma Against Addiction Devastates Pain Patients” [Elizabeth Brico at Filter, a recent launch on drug policy]
- “Why Opioid Pharma Hatred Is Overblown and Harmful” [Alison Knopf, Filter] A Washington Post series on pill distribution fueled a false narrative [Singer, Jacob Sullum, and they’re just getting started]
- “Patients, Privacy, and PDMPs: Exploring the Impact of Prescription Drug Monitoring Programs,” Cato policy forum with David S. Fink, Kate M. Nicholson, Nathan Freed Wessler, and Patience Moyo, moderated by Jeff Singer;
- Oklahoma U. law prof says “improper” opioid nuisance suit by state’s attorney general could “create a monster” [Karen Kidd, Legal Newsline; earlier here, here, etc.] If judge can essentially rewrite public nuisance law, ramifications “are huge” for other industries that might be targeted in future, “such as the environmental, chemical, vaping, firearms manufacturing, and energy industries.” [John Shu, Federalist Society]
Details, always with the picky details: in an opinion written by Justice Jay Mitchell, the Supreme Court of Alabama has thrown out as untimely a tort suit filed against Janssen Biotech Inc. claiming injury from the side effects of a medication. [Charmaine Little, Chamber-backed Legal Newsline] Timeliness wasn’t the only problem with the suit, drafted by the complainant’s attorney wife:
Mitchell noted in the ruling that it was “apparent” from a review of the original complaint that it was copied from another complaint.
“The complaint included numerous factual and legal errors, including an assertion that Tim was dead even though he is alive and claims invoking the laws of Indiana even though that state has no apparent connection to this litigation,” Mitchell wrote.
“A Philadelphia jury [October 8] ordered Johnson & Johnson to pay $8 billion in damages to a Maryland man who said his use of J&J’s antipsychotic Risperdal as a child caused enlarged breasts and the company failed to properly warn of this risk.” [Peter Loftus, Wall Street Journal] According to the company, the jury in the case had not been allowed to hear evidence of Risperdal’s benefits or the adequacy of its labeling, and the plaintiff’s attorney never introduced evidence that the allegedly improper warning made a difference in whether the client would have been exposed to the side effect. [Brendan Pierson and Nate Raymond, Reuters; Mihir Zaveri and Katie Thomas, New York Times] A recusal motion filed by the company also claims that the judge high-fived jurors after the verdict. [Debra Cassens Weiss, ABA Journal] Update Oct. 31: judge denies high-five allegation.
“A judge in Oklahoma on Monday ruled that Johnson & Johnson had intentionally played down the dangers and oversold the benefits of opioids, and ordered it to pay the state $572 million.” The state had asked for $17 billion. [Jan Hoffman, New York Times and sidebar on why J&J, the deepest pocket, was the only defendant left standing in the Oklahoma case; opinion; Paul Demko, Politico; Lenny Bernstein, Washington Post] Caleb Brown interviewed me for the Cato Daily Podcast:
For other skeptical views of the case, see Daniel Fisher, Legal NewsLine (“J&J had about 3% market share, sold abuse-resistant drugs, and Oklahoma didn’t present evidence of a single doctor who was misled by its marketing.”) and followup (problems with state’s legal theory), Jeffrey Singer/Cato, and Jacob Sullum, Reason (sweeping definition of public nuisance) and followup (other problems). [More: Jonathan Turley]
Particularly worth noting is Jacob Sullum’s account of the logical path traced by Judge James Hill in North Dakota in recently dismissing a suit against Purdue Pharma:
One of the claims against the company involved a public nuisance statute very similar to Oklahoma’s. Hill noted that “North Dakota courts have not extended the nuisance statute to cases involving the sale of goods.” He cited a 1993 case in which the Tioga Public School District #15 of Williams County, North Dakota, argued that the sale of acoustical plaster containing asbestos qualified as a public nuisance.
The U.S. Court of Appeals for the 8th Circuit, which handled the case because it involved an out-of-state defendant, observed that “North Dakota cases applying the state’s nuisance statute all appear to arise in the classic context of a landowner or other person in control of property conducting an activity on his land in such a manner as to interfere with the property rights of a neighbor.” The 8th Circuit worried about the consequences of venturing beyond that “classic context”:
To interpret the nuisance statute in the manner espoused by Tioga would in effect totally rewrite North Dakota tort law. Under Tioga’s theory, any injury suffered in North Dakota would give rise to a cause of action under section 43-02-01 regardless of the defendant’s degree of culpability or of the availability of other traditional tort law theories of recovery. Nuisance thus would become a monster that would devour in one gulp the entire law of tort, a development we cannot imagine the North Dakota legislature intended when it enacted the nuisance statute.
Hill said he “agrees with the reasoning of the Eighth Circuit in Tioga.” As in that case, he said, the state in its lawsuit against Purdue was “clearly seeking to extend the application of the nuisance statute to a situation where one party has sold to another a product that later is alleged to constitute a nuisance.” Hill added:
The reality is that Purdue has no control over its product after it is sold to distributors, then to pharmacies, and then prescribed to consumers, i.e. after it enters the market. Purdue cannot control how doctors prescribe its products and it certainly cannot control how individual patients use and respond to its products, regardless of any warning or instruction Purdue may give.
Judging from the cases cited by Judge Balkman, Oklahoma courts have not read that state’s nuisance law to cover situations like this either—until now.
- Starting in mid-1990s German doctors began writing many more opioid prescriptions. But addiction and overdose rates did not skyrocket. What made Germany different? [Jeffrey Singer, Cato; Jacob Sullum, Reason]
- Will the Supreme Court’s unanimous ruling in Merck v. Albrecht manage to clarify preemption law? [Beck, Drug & Device Law and more; Jonah Knobler, Washington Legal Foundation]
- Money didn’t go into state treasury: “Oklahoma Lawmakers not so Happy About Purdue Pharma Settlement” [Sean Murphy, Insurance Journal, more] “Nevada AG’s old law firm can make up to $350 million on his opioid lawsuit” [Daniel Fisher, Legal Newsline] “List of firms handling Louisiana’s opioid lawsuit balloons to 17, including politically connected ones” [Sam Karlin, The Advocate] Richard Epstein on opiate litigation [Ricochet]
- National Vaccine Injury Compensation Program: “Where Calls for Overturning Bruesewitz v. Wyeth Go Wrong” [Dorit Reiss, Petrie-Flom “Bill of Health”]
- “Drug lawsuit ads are scaring seniors to death” [P. Roosevelt Gilliam III and Susan Peschin, STAT]
- Senate Republicans file bill to fast-track FDA consideration of over-the-counter birth control pill [Elizabeth Nolan Brown]
- Why is insulin so expensive? [Tyler Cowen] “People Are Clamoring to Buy Old Insulin Pumps” [Sarah Zhang, The Atlantic via Ted Frank (calling it “an amazing story …about a problem created by overregulation and fear of tort liability, words that never appear in the article”)]
- Opioid litigation might be working to let the policy offenders in government get away [Jeffrey Miron and Laura Nicolae, Real Clear Policy/Cato; Jeffrey Singer, Cato; Charles Fain Lehman, National Review] A contrasting view: Nicolas P. Terry, Petrie-Flom “Bill of Health”;
- Read and marvel: Critical Dietetics, a social justice health movement [James Lindsay on Twitter]
- How HIPAA, the health privacy law, impedes potentially life-saving research into health records [John Cochrane]
- Uh-oh: Pennsylvania Supreme Court move could reopen forum shopping for medical malpractice lawsuits [David Wenner, Penn Live]
- “Transparent Medical Pricing and the $89,000 Snake Bite” [Cato Podcast with Eric Ferguson]
- London ban on transit ads depicting “bad” foods winds up nixing images of Wimbledon strawberries and cream, bacon, butter, cheese, jam, honey, and Christmas pudding [Scott Shackford]
- And more: British medical journal The Lancet wants to do some highly non-consensual poking and jabbing at your midsection, with the aim of making you lose weight; highlights include funding activist campaigns, cutting business out of policy discussions, and routing policy through the least accountable international organizations [Christopher Snowdon, The Spectator; more from Snowdon on state-subsidized anti-food advocacy in Britain; Nina Teicholz]
- Pushing back on the Lancet panel’s guideline that each person be allowed no more than one egg and less than 3.5 ounces of red meat a week [Mark Hemingway]
- “The Problem With Nudging People to Happiness” [Randy Barnett reviews Cass Sunstein’s On Freedom]
- “Pharmaceutical Freedom: Why Patients Have a Right to Self Medicate”, Cato Daily Podcast with Jessica Flanigan and Caleb Brown;
- “Proposed Anti-Soda Bills in California Would Ban Big Gulps, Mandate Warning Labels on Vending Machines” [Christian Britschgi] “Medical Groups Endorse New Taxes and Marketing Restrictions on Soda — For the children, of course” [Baylen Linnekin]
“In terms of the evidence, the trial lawyers [suing Bayer and Johnson & Johnson over the blood thinner Xarelto] had a losing hand — any kind of sane judicial system would have them leaving the field of battle, a defeated army.” But they’d signed up a remarkable 25,000 clients, buying an estimated 129,000 ads seeking such business in 2016, with one law firm alone spending $20 million a year on promotion. When you’ve got that big a base of clients to throw at them, “companies settle meritless cases.” [Joe Nocera, Bloomberg Opinion]
“The Trump Justice Department, following a tougher policy toward dubious False Claims Act lawsuits by private citizens, has moved to dismiss a pair of lawsuits by a former hedge-fund manager who shorted stock in pharmaceutical companies he accused of a wide-ranging price-fixing conspiracy.” [Daniel Fisher, Legal NewsLine/Forbes]
“The scientists and doctors would get excited….But as soon as their lawyers heard ‘sick, pregnant women,’ nothing happened,” Moore said. “There’s such a sense of liability.” [Carolyn Y. Johnson, Washington Post/Bartlesville, Okla., Examiner-Enterprise]